## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ss-31-glp1-gut`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ss-31-glp1-gut/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-glp1-gut/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-glp1-gut/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ss-31-glp1-gut/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-glp1-gut/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ss-31-glp1-gut/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ss-31-glp1-gut` v2 · content_hash `25cbc74e9f49759c…` · thread_head genesis · 24 DIVs
- **thesis (c1):** SS-31 binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae and reducing ROS production.
  - c2 [human/active] One randomized trial showed dose-dependent improvement in 6-minute walk distance in primary mitochondrial myopathy patients after 5 days of elamipretide.
  - c3 [human/active] GLP-1 agonist use was associated with adjusted HR 3.67 for gastroparesis versus comparator in an observational study.
  - c4 [human/active] No human trials have tested SS-31 in gastroparesis or GLP-1 gut damage.
  - c5 [preclinical/active] SS-31 improved mitochondrial function in ex vivo failing human hearts and in rodent models of oxidative stress.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ss-31-glp1-gut/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ss-31-glp1-gut/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ss-31-glp1-gut`
- **title:** SS-31 (Elamipretide) for GLP-1 Agonist Gut Damage: Mitochondrial Evidence Review
- **url:** https://miscsubjects.com/a/ss-31-glp1-gut
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:03.812Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have GLP-1 gut damage / gastroparesis

GLP-1 agonists slow gastric emptying as part of their metabolic action. In some people this effect becomes excessive and leads to symptoms of gastroparesis. The stomach and small intestine rely on smooth muscle cells and enteric neurons that need steady ATP from mitochondria to contract and coordinate movement. When mitochondria in these cells produce excess reactive oxygen species or lose efficient electron transport, energy drops and motility slows further. Oxidative damage to cardiolipin in the inner mitochondrial membrane can worsen cristae structure and ATP output. If your GLP-1 use coincides with persistent delayed emptying, one layer of the problem may be mitochondrial stress in gut tissue rather than only the drug's direct receptor effect. Repair pathways that target this mitochondrial layer differ from simply stopping the drug or masking symptoms.

## Why SS-31 (Elamipretide) might help you

1. You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.
2. Therefore for you: If mitochondrial dysfunction in enteric smooth muscle or neurons is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair at the cardiolipin level inside mitochondria — not because it masks slowed emptying.

SS-31 binds directly to cardiolipin in the inner mitochondrial membrane. This interaction stabilizes cristae structure and supports electron transport chain efficiency. When cardiolipin is protected, electron leak drops and reactive oxygen species production falls. Cells regain better ATP output without the drug needing to act on GLP-1 receptors themselves. In gut tissue where mitochondria are strained, restoring this layer could support the energy needed for normal motility once the primary drug effect is addressed. The compound does not reduce gastric emptying on its own; it addresses a downstream cellular energy layer that may be compromised.

## Why GLP-1 agonists (class) matters for you

**Drug:** GLP-1 agonists (class)
**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.
**Therefore for you:** This drug suppresses a signal for gastric emptying to support blood sugar control and appetite reduction. That suppression helps metabolism but trades off against normal gut motility repair for some users by prolonging delayed emptying.

GLP-1 receptor activation slows stomach emptying to limit post-meal glucose spikes. Observational data link the class to higher reported rates of gastroparesis diagnoses compared with other weight-loss drugs. The effect is dose- and duration-dependent in many cases. When emptying remains delayed for weeks or months, the mechanical and cellular stress on gut mitochondria may increase. Addressing only the mitochondrial layer with another compound does not reverse the receptor-mediated slowing; the two actions operate on different pathways.

## How these fit together

Single-compound focus — SS-31 targets the mitochondrial layer while GLP-1 agonists act on receptor signaling that slows emptying. SS-31 (Elamipretide) addresses mitochondrial cardiolipin stabilization and ATP support. The GLP-1 drug supplies the metabolic signal change but can extend the period of low motility that stresses gut cell mitochondria. The two do not directly interact; one works on cellular energy machinery while the other modulates hormone signaling. If mitochondrial damage accumulates during prolonged GLP-1 use, the mitochondrial repair compound may complement management by supporting the energy layer without altering the primary drug mechanism.

## What the evidence actually shows

Human data on SS-31 come from trials in primary mitochondrial myopathy and heart failure. One randomized trial in primary mitochondrial myopathy showed dose-dependent improvement in six-minute walk distance after five days of intravenous dosing (Class I evidence). Phase 2 and 3 trials in heart failure produced mixed functional results; some biomarkers improved while primary endpoints did not reach significance. A 2025 report noted FDA approval for Barth syndrome, a rare mitochondrial disorder. No human trials have tested SS-31 in gastroparesis or GLP-1-related gut slowing.

Preclinical studies in rodents and cell models demonstrate that SS-31 reduces mitochondrial ROS, preserves cristae, and improves ATP production in cardiac, renal, and neural tissue. One mouse study found protection against lipopolysaccharide-induced mitochondrial dysfunction in the hippocampus. These animal findings establish the cardiolipin-binding mechanism but do not test gut motility or GLP-1 contexts.

A large observational study reported adjusted hazard ratios for gastroparesis of 3.67 (95% CI 1.15-11.90) with GLP-1 agonists versus comparator weight-loss medication. Smaller case series describe delayed emptying confirmed by scintigraphy in patients on semaglutide and similar agents. Human evidence for the mitochondrial layer in enteric neurons remains absent.

## What scientists say

Researchers describe SS-31 as selectively concentrating in mitochondria and stabilizing cardiolipin to limit oxidative damage. Reviews note consistent preclinical benefits across ischemia, aging, and genetic mitochondrial models, with human translation limited to specific rare diseases. Gastroenterologists note that GLP-1 agonist-induced delayed emptying is an expected on-target effect that becomes problematic only when it persists or causes malnutrition. No published commentary links SS-31 directly to gut recovery in this setting.

## What people say on Reddit

Anecdotal reports on SS-31 appear in mitochondrial and chronic fatigue communities. Users describe subjective energy gains and reduced oxidative-stress symptoms after weeks of use, but no posts specifically mention gastroparesis or GLP-1 gut issues. Discussions of GLP-1 agonists frequently note nausea and slowed digestion that resolve after discontinuation for most users.

## What people say on X

Public posts on X about SS-31 focus on mitochondrial health in aging or rare disease contexts. Mentions of GLP-1 gut side effects are common but do not reference SS-31 or mitochondrial repair peptides in the same threads. No verified user reports combine the two topics.

## What we do not know

No clinical studies measure SS-31 effects on gastric emptying, enteric neuron mitochondria, or GLP-1 agonist users with gastroparesis. Human gut biopsy data showing cardiolipin changes during GLP-1 therapy are unavailable. Long-term safety of combining SS-31 with ongoing GLP-1 agonists has not been examined. Dose-response relationships for any gut-related outcome remain unknown.

## Safety and limits

SS-31 has been well tolerated in short-term human trials with mild adverse events such as headache or fatigue reported in some participants. Gastrointestinal side effects appear infrequently in existing data. The compound remains investigational outside approved rare-disease indications. GLP-1 agonists carry their own boxed warnings and documented gastrointestinal risks. Any consideration of additional compounds requires individualized medical supervision; this review presents published evidence only and does not constitute guidance.

## Claims (5)

- **c4** [human w=0.8] No human trials have tested SS-31 in gastroparesis or GLP-1 gut damage.
  - who_claims: grok/grok-4.3
- **c1** [mechanistic w=0.3] SS-31 binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae and reducing ROS production.
  - who_claims: grok/grok-4.3
  - sources: s9, s10
- **c2** [human w=0.8] One randomized trial showed dose-dependent improvement in 6-minute walk distance in primary mitochondrial myopathy patients after 5 days of elamipretide.
  - who_claims: grok/grok-4.3
  - sources: s28
- **c3** [human w=0.8] GLP-1 agonist use was associated with adjusted HR 3.67 for gastroparesis versus comparator in an observational study.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c5** [preclinical w=0.5] SS-31 improved mitochondrial function in ex vivo failing human hearts and in rodent models of oxidative stress.
  - who_claims: grok/grok-4.3
  - sources: s12, s16

## Voxel graph (5 atoms · 11 edges)
- full graph: https://miscsubjects.com/api/articles/ss-31-glp1-gut/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (6)
- chain valid: yes · head: `9885394fe8e86157`

### s3 · pubmed · http_403
- title: GLP-1 Agonists and Gastrointestinal Adverse Events
- url: https://jamanetwork.com/journals/jama/fullarticle/2810542
- summary: Observational study on GI risks including gastroparesis with GLP-1 agonists.
- quote: Use of GLP-1 agonists compared with bupropion-naltrexone was associated with increased risk of ... gastroparesis (HR, 3.67 [95% CI, 1.15-11.90])
- claim_ids: c3
- hash: `bbdb283448a72ccc`

### s9 · pubmed · ok
- title: Elamipretide: A Review of Its Structure, Mechanism of Action ...
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/
- summary: Review of SS-31 mechanism via cardiolipin binding.
- quote: The stabilization of cardiolipin by Elamipretide results in improved mitochondrial function, reduced oxidative stress, and mitigated cell damage
- claim_ids: c1
- hash: `48d133bdff37d874`

### s10 · review · http_403
- title: Elamipretide - an overview
- url: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/elamipretide
- summary: Overview confirming mitochondrial targeting.
- quote: Elamipretide ... selectively binds cardiolipin ... leading to reduced mitochondrial reactive oxygen species (ROS) generation and improved ATP production.
- claim_ids: c1
- hash: `2657acdc0fd2ee0d`

### s12 · review · ok
- title: SS-31 (also known as Elamipretide®...) Cognitive Vitality For Researchers
- url: https://www.alzdiscovery.org/uploads/cognitive_vitality_media/SS-31-Cognitive-Vitality-For-Researchers.pdf
- summary: Summary of human tissue and preclinical data.
- quote: In an ex vivo study of failing human hearts, SS-31 treatment improved mitochondrial function
- claim_ids: c5
- hash: `9295f708b80697d1`

### s16 · pubmed · ok
- title: Late-life restoration of mitochondrial function reverses ...
- url: https://elifesciences.org/articles/55513
- summary: Rodent study on mitochondrial restoration in aging heart.
- quote: We show here that 8-week treatment of old mice with ... SS-31 ... can substantially reverse this deficit.
- claim_ids: c5
- hash: `d37452a29a02b585`

### s28 · pubmed · ok
- title: Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
- url: https://www.neurology.org/doi/10.1212/WNL.0000000000005255
- summary: Human trial showing functional improvement in PMM.
- quote: Participants who received the highest dose of elamipretide walked a mean of 64.5 m farther at day 5 compared to a change of 20.4 m in the placebo group
- claim_ids: c2
- hash: `9885394fe8e86157`

## Provenance (2 model passes)
- chain valid: yes · head: `446ca43d0f7147c2`

- write · grok/grok-4.3 · 2026-06-29T23:54 · hash `3d6bda0df15c`
- voxel_divide · owner · 2026-07-17T02:42 · hash `446ca43d0f71`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ss-31-glp1-gut/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ss-31-glp1-gut/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ss-31-glp1-gut","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ss-31-glp1-gut|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ss-31-glp1-gut|tier|assertion`
- **iMessage ask:** `ss-31-glp1-gut|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ss-31-glp1-gut`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-glp1-gut/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-glp1-gut/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*